EA032955B3 - Применение производного глутаримида для лечения эозинофильных заболеваний - Google Patents

Применение производного глутаримида для лечения эозинофильных заболеваний

Info

Publication number
EA032955B3
EA032955B3 EA201891262A EA201891262A EA032955B3 EA 032955 B3 EA032955 B3 EA 032955B3 EA 201891262 A EA201891262 A EA 201891262A EA 201891262 A EA201891262 A EA 201891262A EA 032955 B3 EA032955 B3 EA 032955B3
Authority
EA
Eurasian Patent Office
Prior art keywords
eosinophilic
treatment
diseases
eosinophilic diseases
syndrome
Prior art date
Application number
EA201891262A
Other languages
English (en)
Russian (ru)
Other versions
EA032955B1 (ru
EA201891262A1 (ru
Inventor
Владимир Евгеньевич НЕБОЛЬСИН
Татьяна Александровна КРОМОВА
Анастасия Владимировна РЫДЛОВСКАЯ
Александр Григорьевич ЧУЧАЛИН
Original Assignee
Общество С Ограниченной Ответственностью "Хемиммьюн Терапьютикс"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество С Ограниченной Ответственностью "Хемиммьюн Терапьютикс" filed Critical Общество С Ограниченной Ответственностью "Хемиммьюн Терапьютикс"
Publication of EA201891262A1 publication Critical patent/EA201891262A1/ru
Publication of EA032955B1 publication Critical patent/EA032955B1/ru
Publication of EA032955B3 publication Critical patent/EA032955B3/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/45Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/04Drugs for disorders of the respiratory system for throat disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86Oxygen atoms
    • C07D211/88Oxygen atoms attached in positions 2 and 6, e.g. glutarimide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EA201891262A 2013-11-14 2014-11-12 Применение производного глутаримида для лечения эозинофильных заболеваний EA032955B3 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2013150861/15A RU2552929C1 (ru) 2013-11-14 2013-11-14 Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний

Publications (3)

Publication Number Publication Date
EA201891262A1 EA201891262A1 (ru) 2018-10-31
EA032955B1 EA032955B1 (ru) 2019-08-30
EA032955B3 true EA032955B3 (ru) 2020-02-27

Family

ID=53057723

Family Applications (4)

Application Number Title Priority Date Filing Date
EA201690798A EA030961B1 (ru) 2013-11-14 2014-11-12 Применение производных глутаримидов для лечения эозинофильных заболеваний
EA201891262A EA032955B3 (ru) 2013-11-14 2014-11-12 Применение производного глутаримида для лечения эозинофильных заболеваний
EA201891261A EA032940B1 (ru) 2013-11-14 2014-11-12 Способ лечения эозинофильных заболеваний с помощью соединения производного глутаримидов
EA201990529A EA037447B1 (ru) 2013-11-14 2014-11-12 Способ лечения эозинофильных заболеваний

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201690798A EA030961B1 (ru) 2013-11-14 2014-11-12 Применение производных глутаримидов для лечения эозинофильных заболеваний

Family Applications After (2)

Application Number Title Priority Date Filing Date
EA201891261A EA032940B1 (ru) 2013-11-14 2014-11-12 Способ лечения эозинофильных заболеваний с помощью соединения производного глутаримидов
EA201990529A EA037447B1 (ru) 2013-11-14 2014-11-12 Способ лечения эозинофильных заболеваний

Country Status (23)

Country Link
US (2) US9949962B2 (fr)
EP (2) EP3069720B1 (fr)
JP (4) JP2016540749A (fr)
KR (2) KR102312294B1 (fr)
CN (2) CN110200968A (fr)
AU (2) AU2014349246C1 (fr)
BR (1) BR112016010515B1 (fr)
CA (1) CA2930231C (fr)
CY (1) CY1122500T1 (fr)
DK (1) DK3069720T3 (fr)
EA (4) EA030961B1 (fr)
ES (2) ES2759530T3 (fr)
HU (1) HUE046671T2 (fr)
IL (2) IL245429B (fr)
LT (1) LT3069720T (fr)
MX (2) MX365781B (fr)
PL (2) PL3069720T3 (fr)
PT (1) PT3069720T (fr)
RU (1) RU2552929C1 (fr)
SG (1) SG10201900504XA (fr)
SI (1) SI3069720T1 (fr)
UA (1) UA118687C2 (fr)
WO (1) WO2015072893A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA033054B1 (ru) * 2013-04-12 2019-08-30 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Производное глутаримидов, его применение, фармацевтическая композиция на его основе, способ его получения
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法
CN106062000B (zh) 2014-02-28 2021-05-28 瑞泽恩制药公司 通过施用il-4r拮抗剂治疗皮肤感染的方法
CA3035202A1 (fr) 2016-09-01 2018-03-08 Regeneron Pharmaceuticals, Inc. Methodes de prevention ou de traitement de l'allergie par administration d'un antagoniste d'il-4 r
CN106539792B (zh) * 2016-11-07 2017-08-25 王晓旭 一种治疗高血脂症的药物
GEP20227402B (en) 2017-09-07 2022-08-10 Valenta Intellekt Ltd Use of glutarimide derivative to treat diseases related to aberrant activity of cytokines
RU2712281C1 (ru) * 2018-11-23 2020-01-28 Общество С Ограниченной Ответственностью "Хемиммьюн Терапьютикс" Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма
WO2020191346A1 (fr) 2019-03-21 2020-09-24 Regeneron Pharmaceuticals, Inc. Combinaison d'inhibiteurs de la voie il-4/il-13 et d'ablation de plasmocytes pour traiter une allergie
JP2022543815A (ja) 2019-08-05 2022-10-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Il-4rアンタゴニストを投与することによりアレルギーを治療しアレルゲン特異的免疫療法を増強するための方法
JP2022543612A (ja) 2019-08-05 2022-10-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Il-4rアンタゴニストを投与することによるアトピー性皮膚炎の治療方法
BR112022026356A2 (pt) * 2020-06-26 2023-01-17 Valenta Intellekt Ltd Uso de um derivado de glutarimida para tratar doenças associadas à atividade aberrante da interleucina-6
WO2023113650A1 (fr) * 2021-12-15 2023-06-22 Владимир Евгеньевич НЕБОЛЬСИН Composition pharmaceutique de 1-[2-(1-méthylimidazol-4-yl)-éthyl]perhydroazine-2,6-dione pour le traitement de maladies des voies respiratoires supérieures

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994024133A1 (fr) * 1993-04-09 1994-10-27 Cell Therapeutics, Inc. Inhibiteurs de signalisation cellulaire a cycle substitue
WO2007000246A1 (fr) * 2005-06-28 2007-01-04 Sanofi-Aventis Amides à substitution hétéroaryle comprenant un groupe de liaison saturé, et leur utilisation en tant que produits pharmaceutiques
RU2378284C2 (ru) * 2008-02-13 2010-01-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Способы получения n-ацильных производных аминокислот (варианты)
RU2406727C2 (ru) * 2008-02-13 2010-12-20 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фармацевтическая композиция, содержащая n-ацильные производные аминокислот, и их применение в качестве противоаллергических, антианафилактических и противовоспалительных средств

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02196767A (ja) * 1988-10-11 1990-08-03 Kyowa Hakko Kogyo Co Ltd ヒドロキサム酸誘導体
EP0564520A1 (fr) * 1990-12-24 1993-10-13 Merrell Dow Pharmaceuticals Inc. Utilisation de certains derives de glutarimide dans le traitement de la depression et des etats maniaques
AUPO005496A0 (en) 1996-05-24 1996-06-13 Bresagen Limited An interleukin-5 antagonist
RU2141483C1 (ru) 1997-07-04 1999-11-20 Небольсин Владимир Евгеньевич Производные пептидов или их фармацевтически приемлемые соли, способ их получения, применение и фармацевтическая композиция
NZ532516A (en) 2001-11-07 2008-05-30 Cytos Biotechnology Ag Antigen arrays presenting IL-5, IL-13 or eotaxin for treatment of allergic eosinophilic diseases
WO2007007054A1 (fr) 2005-07-08 2007-01-18 Cancer Research Technology Limited Phthalamides, succinimides, composes apparentes et leur utilisation en tant que produits pharmaceutiques
KR101588061B1 (ko) 2007-05-14 2016-01-25 메디뮨 엘엘씨 호산구 수준을 감소시키는 방법
EA033054B1 (ru) * 2013-04-12 2019-08-30 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Производное глутаримидов, его применение, фармацевтическая композиция на его основе, способ его получения

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994024133A1 (fr) * 1993-04-09 1994-10-27 Cell Therapeutics, Inc. Inhibiteurs de signalisation cellulaire a cycle substitue
WO2007000246A1 (fr) * 2005-06-28 2007-01-04 Sanofi-Aventis Amides à substitution hétéroaryle comprenant un groupe de liaison saturé, et leur utilisation en tant que produits pharmaceutiques
RU2378284C2 (ru) * 2008-02-13 2010-01-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Способы получения n-ацильных производных аминокислот (варианты)
RU2406727C2 (ru) * 2008-02-13 2010-12-20 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фармацевтическая композиция, содержащая n-ацильные производные аминокислот, и их применение в качестве противоаллергических, антианафилактических и противовоспалительных средств

Also Published As

Publication number Publication date
KR102312013B1 (ko) 2021-10-15
ES2759530T3 (es) 2020-05-11
EP3069720B1 (fr) 2019-10-30
EP3069720A8 (fr) 2017-10-04
ES2836887T3 (es) 2021-06-28
MX2016006330A (es) 2016-09-06
EA201690798A1 (ru) 2016-08-31
IL245429B (en) 2020-02-27
EP3466425A1 (fr) 2019-04-10
AU2014349246C1 (en) 2019-02-21
US20160279114A1 (en) 2016-09-29
CN110200968A (zh) 2019-09-06
AU2018264084A1 (en) 2018-12-06
CN105722511B (zh) 2019-09-17
DK3069720T3 (da) 2019-11-25
AU2014349246A9 (en) 2018-09-20
EA032955B1 (ru) 2019-08-30
AU2014349246B2 (en) 2018-10-18
RU2013150861A (ru) 2015-05-20
BR112016010515A2 (fr) 2017-08-08
JP2016540749A (ja) 2016-12-28
AU2018264084B2 (en) 2020-05-14
EA030961B1 (ru) 2018-10-31
EA032940B1 (ru) 2019-08-30
MX365781B (es) 2019-06-13
KR20160078400A (ko) 2016-07-04
MX2019006881A (es) 2019-08-01
SI3069720T1 (sl) 2020-02-28
EP3069720A4 (fr) 2017-06-21
IL271352B (en) 2021-04-29
AU2018264084C1 (en) 2020-08-27
CA2930231A1 (fr) 2015-05-21
JP2019055953A (ja) 2019-04-11
EA037447B1 (ru) 2021-03-30
UA118687C2 (uk) 2019-02-25
HUE046671T2 (hu) 2020-03-30
US9949962B2 (en) 2018-04-24
WO2015072893A1 (fr) 2015-05-21
JP6758677B2 (ja) 2020-09-23
JP2019214606A (ja) 2019-12-19
BR112016010515B1 (pt) 2022-09-27
EA201891262A1 (ru) 2018-10-31
US20180104230A1 (en) 2018-04-19
PL3069720T3 (pl) 2020-05-18
JP2020002152A (ja) 2020-01-09
CY1122500T1 (el) 2021-01-27
PL3466425T3 (pl) 2021-04-06
EA201891261A1 (ru) 2018-10-31
US10220029B2 (en) 2019-03-05
KR102312294B1 (ko) 2021-10-15
IL245429A0 (en) 2016-06-30
EA201990529A1 (ru) 2019-07-31
PT3069720T (pt) 2019-12-02
LT3069720T (lt) 2020-01-10
JP6589251B2 (ja) 2019-10-16
AU2014349246A1 (en) 2016-05-19
IL271352A (en) 2020-01-30
RU2552929C1 (ru) 2015-06-10
EP3069720A1 (fr) 2016-09-21
CA2930231C (fr) 2022-06-14
CN105722511A (zh) 2016-06-29
KR20200053639A (ko) 2020-05-18
SG10201900504XA (en) 2019-02-27
EP3466425B1 (fr) 2020-10-07

Similar Documents

Publication Publication Date Title
EA032955B3 (ru) Применение производного глутаримида для лечения эозинофильных заболеваний
MX2015012866A (es) Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica.
MX2022004103A (es) Una formulacion de rapamicina inhalable para tratar afecciones relacionadas con la edad.
MX2017004471A (es) Compuestos de triazolopiridina y métodos para el tratamiento de fibrosis cística.
MX363243B (es) Composiciones para tratar cáncer y usos de dichas composiciones.
MX362185B (es) Composiciones y tratamiento para enfermedades y trastornos del ojo.
NZ726366A (en) Syk inhibitors
IN2015DN00450A (fr)
NZ719185A (en) Crystalline forms of therapeutic compounds and uses thereof
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
EA201591290A2 (ru) Креноланиб для лечения пролиферативных расстройств, связанных с мутацией flt3
MX2018006247A (es) Metodos para tratar la enfermedad de alzheimer y trastornos relacionados.
WO2012080497A3 (fr) Procédés de traitement et de prévention de maladies oculaires
EA201290603A1 (ru) Способ лечения
MX2014002394A (es) Inhibidores de rock suaves, novedosos.
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
MX2021014120A (es) Tratamiento de los sintomas asociados a terapia privacion de androgenos.
WO2014138616A3 (fr) Composés pyrazoles et leurs procédés d'utilisation
HK1216233A1 (zh) 含有四氫吡喃基氨基環戊基羰基四氫吡啶並吡啶衍生物作為有效成分的眼後段疾病的預防或治療劑
PH12014502400A1 (en) Treatment method for steroid responsive dermatoses
MX2016002139A (es) Composicion farmaceutica y uso del (2-cianoetil)fosfonato de dietilo.
WO2011085288A3 (fr) Procédé d'administration et de traitement

Legal Events

Date Code Title Description
PC1A Registration of transfer to a eurasian application by force of assignment
LD4A Eurasian patent limited on request of patent holder (b3)
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG TJ TM